Recent Analysts’ Ratings Updates for Edwards Lifesciences (EW)

Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:

• 10/1/2024 – Edwards Lifesciences had its price target lowered by analysts at Evercore ISI from $76.00 to $70.00. They now have an “in-line” rating on the stock.
• 10/1/2024 – Edwards Lifesciences had its price target lowered by analysts at Citigroup Inc. from $83.00 to $77.00. They now have a “buy” rating on the stock.
• 9/18/2024 – Edwards Lifesciences was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $70.00 price target on the stock, down previously from $85.00.
• 9/13/2024 – Edwards Lifesciences had its price target lowered by analysts at Truist Financial Co. from $82.00 to $71.00. They now have a “hold” rating on the stock.
• 9/12/2024 – Edwards Lifesciences had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $90.00 price target on the stock.
• 9/10/2024 – Edwards Lifesciences had its price target lowered by analysts at UBS Group AG from $90.00 to $75.00. They now have a “neutral” rating on the stock.
• 9/9/2024 – Edwards Lifesciences had its price target lowered by analysts at Barclays PLC from $90.00 to $80.00. They now have an “overweight” rating on the stock.
• 9/9/2024 – Edwards Lifesciences had its price target lowered by analysts at Wells Fargo & Company from $90.00 to $80.00. They now have an “overweight” rating on the stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $65.09 on Wednesday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The stock has a market cap of $39.22 billion, a P/E ratio of 28.05, a P/E/G ratio of 2.80 and a beta of 1.13. The business’s 50 day moving average price is $66.90 and its 200-day moving average price is $81.50.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s revenue was up 6.7% on a year-over-year basis. During the same period last year, the company earned $0.66 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,250 shares of company stock valued at $1,218,138. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Crewe Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences during the second quarter valued at approximately $29,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences during the first quarter valued at approximately $34,000. Webster Bank N. A. bought a new position in Edwards Lifesciences in the second quarter worth approximately $39,000. Finally, Rise Advisors LLC boosted its stake in shares of Edwards Lifesciences by 125.0% during the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after acquiring an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.